Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 23 |
| List of Tables | 20 | 3 |
| List of Figures | 23 | 2 |
| Introduction | 25 | 1 |
| Global Markets Direct Report Coverage | 25 | 1 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview | 26 | 1 |
| Therapeutics Development | 27 | 2 |
| Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview | 27 | 1 |
| Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Comparative Analysis | 28 | 1 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Development by Companies | 29 | 6 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics under Investigation by Universities/Institutes | 35 | 2 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Products Glance | 37 | 3 |
| Late Stage Products | 37 | 1 |
| Clinical Stage Products | 38 | 1 |
| Early Stage Products | 39 | 1 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Products under Development by Companies | 40 | 10 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Products under Investigation by Universities/Institutes | 50 | 2 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Companies Involved in Therapeutics Development | 52 | 83 |
| AB Science SA | 52 | 1 |
| AbbVie Inc | 53 | 1 |
| Adamis Pharmaceuticals Corporation | 54 | 1 |
| Advaxis, Inc. | 55 | 1 |
| Aeterna Zentaris Inc. | 56 | 1 |
| Ambrx, Inc. | 57 | 1 |
| Amgen Inc. | 58 | 1 |
| AnGes MG, Inc. | 59 | 1 |
| Aphios Corporation | 60 | 1 |
| ARMO Biosciences, Inc. | 61 | 1 |
| Armour Therapeutics Inc. | 62 | 1 |
| Arno Therapeutics, Inc. | 63 | 1 |
| ArQule, Inc. | 64 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 65 | 1 |
| Arvinas, Inc. | 66 | 1 |
| Asana BioSciences, LLC | 67 | 1 |
| Astellas Pharma Inc. | 68 | 1 |
| AstraZeneca Plc | 69 | 1 |
| ATLAB Pharma SAS | 70 | 1 |
| Bavarian Nordic A/S | 71 | 1 |
| Bayer AG | 72 | 1 |
| Bio-Cancer Treatment International Limited | 73 | 1 |
| Biscayne Pharmaceuticals, Inc. | 74 | 1 |
| Boehringer Ingelheim GmbH | 75 | 1 |
| Bristol-Myers Squibb Company | 76 | 1 |
| CellCentric Ltd | 77 | 1 |
| Celldex Therapeutics, Inc. | 78 | 1 |
| Corcept Therapeutics Incorporated | 79 | 1 |
| Corvus Pharmaceuticals, Inc. | 80 | 1 |
| Curevac AG | 81 | 1 |
| CytoVac A/S | 82 | 1 |
| DexTech Medical AB | 83 | 1 |
| Eli Lilly and Company | 84 | 1 |
| Enceladus Pharmaceuticals BV | 85 | 1 |
| Endo Pharmaceuticals Inc. | 86 | 1 |
| Endocyte, Inc. | 87 | 1 |
| Errant Gene Therapeutics, LLC | 88 | 1 |
| ESSA Pharma Inc | 89 | 1 |
| F. Hoffmann-La Roche Ltd. | 90 | 1 |
| Fujifilm Corporation | 91 | 1 |
| G1 Therapeutics, Inc. | 92 | 1 |
| Genentech, Inc. | 93 | 1 |
| Genmab A/S | 94 | 1 |
| Gilead Sciences, Inc. | 95 | 1 |
| Glactone Pharma AB | 96 | 1 |
| GlaxoSmithKline Plc | 97 | 1 |
| GTx, Inc. | 98 | 1 |
| Hybrigenics S.A. | 99 | 1 |
| Immunomedics, Inc. | 100 | 1 |
| Io Therapeutics, Inc. | 101 | 1 |
| Ionis Pharmaceuticals, Inc. | 102 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 103 | 1 |
| Johnson &Johnson | 104 | 1 |
| Jyant Technologies, Inc. | 105 | 1 |
| Kura Oncology, Inc. | 106 | 1 |
| MedImmune, LLC | 107 | 1 |
| Mediolanum farmaceutici S.p.A. | 108 | 1 |
| Medivation, Inc. | 109 | 1 |
| MEI Pharma, Inc. | 110 | 1 |
| Merck KGaA | 111 | 1 |
| Millennium Pharmaceuticals Inc | 112 | 1 |
| NewLink Genetics Corporation | 113 | 1 |
| Novartis AG | 114 | 1 |
| Oncogenex Pharmaceuticals, Inc. | 115 | 1 |
| Oncolytics Biotech Inc. | 116 | 1 |
| Ono Pharmaceutical Co., Ltd. | 117 | 1 |
| Oric Pharmaceuticals Inc | 118 | 1 |
| Orion Oyj | 119 | 1 |
| Orphagen Pharmaceuticals, Inc. | 120 | 1 |
| Pfizer Inc. | 121 | 1 |
| Progenics Pharmaceuticals, Inc. | 122 | 1 |
| Selexel | 123 | 1 |
| Sotio a.s. | 124 | 1 |
| Supratek Pharma Inc. | 125 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 126 | 1 |
| Takeda Pharmaceutical Company Limited | 127 | 1 |
| Tesaro, Inc. | 128 | 1 |
| Tiltan Pharma Ltd. | 129 | 1 |
| Tokai Pharmaceuticals, Inc. | 130 | 1 |
| TRACON Pharmaceuticals, Inc. | 131 | 1 |
| UbiVac, LLC | 132 | 1 |
| Viralytics Ltd. | 133 | 1 |
| Zenith Capital Corp | 134 | 1 |
| Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Assessment | 135 | 20 |
| Assessment by Monotherapy Products | 135 | 1 |
| Assessment by Combination Products | 136 | 1 |
| Assessment by Target | 137 | 7 |
| Assessment by Mechanism of Action | 144 | 7 |
| Assessment by Route of Administration | 151 | 2 |
| Assessment by Molecule Type | 153 | 2 |
| Drug Profiles | 155 | 482 |
| abiraterone acetate Drug Profile | 155 | 6 |
| abiraterone acetate Drug Profile | 161 | 1 |
| Adipotide Drug Profile | 162 | 2 |
| ADXS-PSA Drug Profile | 164 | 3 |
| afuresertib hydrochloride Drug Profile | 167 | 3 |
| Alecsat Drug Profile | 170 | 2 |
| alisertib Drug Profile | 172 | 5 |
| alvocidib hydrochloride Drug Profile | 177 | 1 |
| AM-0010 Drug Profile | 178 | 3 |
| AMPI-109 Drug Profile | 181 | 1 |
| apalutamide Drug Profile | 182 | 4 |
| apatorsen Drug Profile | 186 | 6 |
| APC-200 Drug Profile | 192 | 2 |
| APC-300 Drug Profile | 194 | 2 |
| APH-0701 Drug Profile | 196 | 1 |
| APH-1201 Drug Profile | 197 | 1 |
| APP-111 Drug Profile | 198 | 1 |
| AR-42 Drug Profile | 199 | 2 |
| ARV-771 Drug Profile | 201 | 1 |
| ASN-001 Drug Profile | 202 | 1 |
| AT-001 Drug Profile | 203 | 1 |
| ATL-101 Drug Profile | 204 | 2 |
| avelumab Drug Profile | 206 | 6 |
| AZD-3965 Drug Profile | 212 | 2 |
| AZD-5363 Drug Profile | 214 | 3 |
| AZD-8186 Drug Profile | 217 | 1 |
| BAY-1024767 Drug Profile | 218 | 1 |
| BCT-100 Drug Profile | 219 | 2 |
| BI-836845 Drug Profile | 221 | 2 |
| BIND-014 Drug Profile | 223 | 6 |
| BIS-1602 Drug Profile | 229 | 2 |
| BMTP-11 Drug Profile | 231 | 1 |
| buparlisib hydrochloride Drug Profile | 232 | 5 |
| C-1748 Drug Profile | 237 | 2 |
| cabazitaxel Drug Profile | 239 | 1 |
| carfilzomib Drug Profile | 240 | 12 |
| cavatak Drug Profile | 252 | 10 |
| CDX-1401 Drug Profile | 262 | 3 |
| Cellular Immunotherapy 1 for Metastatic Melanoma and Metastatic Castration Resistant Prostate Cancer Drug Profile | 265 | 1 |
| Cellular Immunotherapy 2 for Metastatic Melanoma and Metastatic Castration Resistant Prostate Cancer Drug Profile | 266 | 1 |
| Cellular Immunotherapy for Hormone Refractory Prostate Cancer Drug Profile | 267 | 2 |
| Cellular Immunotherapy for Oncology Drug Profile | 269 | 1 |
| Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 270 | 1 |
| Cellular Immunotherapy to Target PSMA for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 271 | 1 |
| CFI-402257 Drug Profile | 272 | 1 |
| CG-1521 Drug Profile | 273 | 1 |
| CIM-1 Drug Profile | 274 | 1 |
| CORT-125134 Drug Profile | 275 | 2 |
| CPI-444 Drug Profile | 277 | 3 |
| crizotinib Drug Profile | 280 | 7 |
| CV-9103 Drug Profile | 287 | 2 |
| CV-9104 Drug Profile | 289 | 2 |
| dactolisib tosylate + EPI-002 Drug Profile | 291 | 1 |
| dexamethasone acetate Drug Profile | 292 | 1 |
| DpC Drug Profile | 293 | 1 |
| DPV-001 Drug Profile | 294 | 2 |
| DS-1647 Drug Profile | 296 | 1 |
| DT-1154 Drug Profile | 297 | 1 |
| durvalumab Drug Profile | 298 | 10 |
| EC-1169 Drug Profile | 308 | 1 |
| emibetuzumab Drug Profile | 309 | 2 |
| EN-3356 Drug Profile | 311 | 1 |
| enzalutamide Drug Profile | 312 | 15 |
| EPI-001 Drug Profile | 327 | 1 |
| EPI-506 Drug Profile | 328 | 2 |
| ES-414 Drug Profile | 330 | 2 |
| everolimus Drug Profile | 332 | 12 |
| G-1T38 Drug Profile | 344 | 2 |
| galeterone Drug Profile | 346 | 6 |
| ganetespib Drug Profile | 352 | 14 |
| gedatolisib Drug Profile | 366 | 2 |
| GEN-0101 Drug Profile | 368 | 2 |
| GPA-500 Drug Profile | 370 | 1 |
| GPA-512 Drug Profile | 371 | 1 |
| GS-5829 Drug Profile | 372 | 1 |
| GSK-2636771 Drug Profile | 373 | 1 |
| GSK-2849330 Drug Profile | 374 | 1 |
| GSK-525762 Drug Profile | 375 | 1 |
| GT-0918 Drug Profile | 376 | 1 |
| GTx-758 Drug Profile | 377 | 3 |
| GX-301 Drug Profile | 380 | 1 |
| idasanutlin Drug Profile | 381 | 2 |
| indoximod Drug Profile | 383 | 5 |
| inecalcitol Drug Profile | 388 | 6 |
| IONIS-AR-2.5Rx Drug Profile | 394 | 2 |
| ipatasertib Drug Profile | 396 | 2 |
| irofulven Drug Profile | 398 | 2 |
| IRX-4204 Drug Profile | 400 | 2 |
| ITK-1 Drug Profile | 402 | 1 |
| JT-03 Drug Profile | 403 | 1 |
| KRM-20 Drug Profile | 404 | 1 |
| lirilumab Drug Profile | 405 | 4 |
| LY-3022855 Drug Profile | 409 | 1 |
| LY-3023414 Drug Profile | 410 | 2 |
| masitinib Drug Profile | 412 | 13 |
| MIA-602 Drug Profile | 425 | 1 |
| mifepristone Drug Profile | 426 | 6 |
| Monoclonal Antibody Drug Conjugate to Target PSMA for Glioblastoma Multiforme and Castration-Resistant Prostate Cancer Drug Profile | 432 | 1 |
| MVI-816 Drug Profile | 433 | 2 |
| navitoclax dihydrochloride Drug Profile | 435 | 2 |
| niraparib Drug Profile | 437 | 5 |
| nivolumab Drug Profile | 442 | 31 |
| ODM-201 Drug Profile | 473 | 4 |
| ODM-204 Drug Profile | 477 | 1 |
| olaparib Drug Profile | 478 | 9 |
| onapristone ER Drug Profile | 487 | 7 |
| ONC-113B Drug Profile | 494 | 1 |
| Osteodex Drug Profile | 495 | 1 |
| ozarelix Drug Profile | 496 | 2 |
| palbociclib Drug Profile | 498 | 11 |
| pasireotide ER Drug Profile | 509 | 3 |
| pasotuxizumab Drug Profile | 512 | 2 |
| pelareorep Drug Profile | 514 | 15 |
| Peptides to Inhibit Siah2 for Oncology Drug Profile | 529 | 1 |
| PF-06753512 Drug Profile | 530 | 1 |
| pracinostat Drug Profile | 531 | 6 |
| prexasertib Drug Profile | 537 | 2 |
| PSMA ADC Drug Profile | 539 | 4 |
| radium Ra 223 dichloride Drug Profile | 543 | 8 |
| ribociclib succinate Drug Profile | 551 | 4 |
| rilimogene galvacirepvec Drug Profile | 555 | 5 |
| sacituzumab Drug Profile | 560 | 8 |
| seviteronel Drug Profile | 568 | 2 |
| SHR-3680 Drug Profile | 570 | 1 |
| Small Molecule to Antagonize Androgen Receptor for Prostate Cancer Drug Profile | 571 | 1 |
| Small Molecule to Antagonize Glucocorticoid Receptor for Castration-Resistant Prostate Cancer Drug Profile | 572 | 1 |
| Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer Drug Profile | 573 | 1 |
| Small Molecules for Metastatic Castration Resistant Prostate Cancer Drug Profile | 574 | 1 |
| Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer Drug Profile | 575 | 1 |
| Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer Drug Profile | 576 | 1 |
| Small Molecules to Antagonize Androgen Receptor for Metastatic Castration Resistant Prostate Cancer Drug Profile | 577 | 1 |
| Small Molecules to Antagonize Androgen Receptor for Metastatic Hormone Refractory Prostate Cancer Drug Profile | 578 | 1 |
| Small Molecules to Antagonize GNRHR for Prostate Cancer Drug Profile | 579 | 1 |
| Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease Drug Profile | 580 | 1 |
| Small Molecules to Inhibit AKR1C3 for Oncology Drug Profile | 581 | 1 |
| Small Molecules to Inhibit AKR1C3 for Prostate Cancer and Castration Resistant Prostate Cancer Drug Profile | 582 | 1 |
| Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer Drug Profile | 583 | 1 |
| Small Molecules to Inhibit Menin for Mixed-Lineage Acute Leukemia and Hormone Refractory Prostate Cancer Drug Profile | 584 | 2 |
| Small Molecules to Inhibit UGDH for Castration-Resistant Prostate Cancer and Prostate Cancer Drug Profile | 586 | 1 |
| Somadex Drug Profile | 587 | 1 |
| sonidegib phosphate Drug Profile | 588 | 4 |